Podcasts about cancer treatments

Dr. Patrick Soon-Shiong has been a pioneer, leading the way in cancer research. As the Founder,  Executive Chairman, Global Chief Medical & Technology Officer at ImmunityBio, Dr. Soon-Shiong is changing the paradigm in how to treat cancer. Our body needs a strong, healthy immune response to overcome cancer. Chemotherapy weakens the immune system significantly, essentially wiping out our body's best defense of cancer and tumors, the natural killer cell. The natural killer cells in our body destroy and kill cancer cells, without them, we are fighting a losing battle. Dr. Soon-Shiong's invention Anktiva, is a superagonist fusion complex that selectively activates Natural Killer (NK) cells and memory T cells enabling immune amplification rather than immune suppression. This treatment has shown long term success with over a million pages of data. This data is sitting in the hands of the FDA, but unfortunately our FDA has not reviewed it. Saudi Arabia on the other hand, has chosen longevity science and healthspan as a measure of GDP and has approved Anktiva for use in the country. This 30 minute outpatient procedure is now available in Saudi Arabia for patients dealing with cancer. Will the success of this treatment in Saudi Arabia convince the FDA to approve this treatment in America or will Americans be forced into medical tourism to treat cancer successfully and save lives? Featuring: Dr. Patrick Soon-Shiong Executive Chairman, Global Chief Medical & Technology Officer | ImmunityBio https://immunitybio.com/ My latest book Trump 2.0: The Revolution That Will Permanently Transform America is available for preorder, just click the link: https://a.co/d/67kKgje Today's show is sponsored by: Patriot Mobile Take a stand for faith, family, and freedom—switch to Patriot Mobile. Patriot Mobile provides PREMIUM service on all three major U.S. networks. Patriot Mobile is the same or even better coverage, backed by 100% U.S.-based customer support. Get unlimited data plans, mobile hotspots, international roaming, and more with Patriot Mobile. Take a stand as a PATRIOT by going to https://PatriotMobile.com/SPICER or call 972-PATRIOT for a FREE month! Joi + Blokes Are you dragging through your days with no energy, zero motivation and stubborn belly fat? That dad bod, brain fog, and lack of drive aren't character flaws—they're symptoms, usually tied to hormones. Joi + Blokes connects you with licensed clinicians that can tell you what's going on in your body and create a plan to fix it. TRT, peptide therapy, NAD+, enclomiphene—these are treatments that get to the root cause and help you feel stronger, sharper, and present. So, stop guessing and start getting answers. Head to http://joiandblokes.com/sean right now and use code sean for 50% OFF your labs and 20% OFF all supplements! ------------------------------------------------------------- 1️⃣ Subscribe and ring the bell for new videos: https://youtube.com/seanmspicer?sub_confirmation=1 2️⃣ Become a part of The Sean Spicer Show community: https://www.seanspicer.com/ 3️⃣ Listen to the full audio show on all platforms: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-sean-spicer-show/id1701280578 Spotify: https://open.spotify.com/show/32od2cKHBAjhMBd9XntcUd iHeart: https://www.iheart.com/podcast/269-the-sean-spicer-show-120471641/ 4️⃣ Stay in touch with Sean on social media: Facebook: https://facebook.com/seanmspicer Twitter: https://twitter.com/seanspicer Instagram: https://instagram.com/seanmspicer/ 5️⃣ Follow The Sean Spicer Show on social media: Facebook: https://facebook.com/seanspicershow Twitter: https://twitter.com/seanspicershow Instagram: https://instagram.com/seanspicershow Learn more about your ad choices. Visit megaphone.fm/adchoices

Getting a cancer diagnosis today can mean something very different than it meant a few decades ago.  Cancer is still deadly. But thanks to advances in detection and treatment, cancer for some people has turned into a manageable condition. A report from the American Cancer Society out this week shows that for the first time that the five-year survival rate for all cancers has reached 70 percent. Tumors are being found at earlier stages, when treatment can be more effective. Surgery and radiation have gotten more precise.  Researchers have refined their understanding of different types of cancers and developed new drugs that zero in on the unique biology of specific tumors.Maybe most importantly, researchers are figuring out how to use the body's own immune system to fight cancer in ways that doctors couldn't have imagined 20 years ago.  MPR News host Angela Davis talks with her guests about how cancer treatments are improving.Guests: Dr. Emil Lou is a medical oncologist and professor at the University of Minnesota Medical School who sees patients at M Health Fairview Masonic Cancer Clinic. He specializes in gastrointestinal cancers, such as colorectal and pancreas cancers, and is also involved in cancer research.  Dr. Rachel L McCaffrey is a breast surgical oncologist at Allina Health who specializes in treating breast cancer. 

In this talk, Rileen, a Senior Computational Biologist and Cancer Data Scientist, shares his professional journey from physics and computer science to cutting-edge cancer genomics and applied machine learning. From his early work in alternative splicing models to deep learning in medical imaging, Rileen explains how biology, data science, and AI intersect to transform cancer research.TIMECODES:00:00 Rileen's Career Journey and Education06:14 Understanding Alternative Splicing in Computational Biology10:56 Modeling Alternative Splicing with Machine Learning14:52 Model Error Analysis and Transition to Cancer Research18:37 What Is Cancer? Mutational Theory Explained21:45 Cancer Treatments and Causes24:57 Cancer Genomics and Tumor Models28:59 Comparing Cell Lines and Tumor Samples (Multi-omics Analysis)32:32 Machine Learning Applications in Cancer Research35:38 Deep Learning for Medical Imaging and Pathology39:17 Data Privacy and Applied ML Course Projects42:50 Learning Outcomes and Future Plans46:36 Industry Experience in Pharmaceutical Research50:14 Day in the Life of a Computational Biologist55:02 Advice for Current ML Students58:40 Project Management and Challenges in Genomics1:02:23 Public Data Sets and Cancer Research in GermanyConnect with Rileen:- Twitter - https://x.com/RileenSinha- Linkedin - https://www.linkedin.com/in/rileen-sinha-a644692/- Github - https://github.com/OptimistixConnect with DataTalks.Club:- Join the community - https://datatalks.club/slack.html- Subscribe to our Google calendar to have all our events in your calendar - https://calendar.google.com/calendar/r?cid=ZjhxaWRqbnEwamhzY3A4ODA5azFlZ2hzNjBAZ3JvdXAuY2FsZW5kYXIuZ29vZ2xlLmNvbQ- Check other upcoming events - https://lu.ma/dtc-events- GitHub: https://github.com/DataTalksClub- LinkedIn - https://www.linkedin.com/company/datatalks-club/ - Twitter - https://twitter.com/DataTalksClub - Website - https://datatalks.club/

In cancer research, the “seed and soil” hypothesis posits that the tumor is like a seed of misbehaving cells taking root in the body. Whether it grows—and where it grows—depends on the conditions, or soil. Since this hypothesis was proposed more than 100 years ago, most research and treatments have focused on the seed, or tumor. For nearly 50 years, Rakesh Jain has been studying the soil. But in a seed-focused field, his work was seen as wasteful and radical. Now, that very same research has led to seven FDA-approved treatments for diseases including lung and liver cancer, and earned him a National Medal of Science in 2016. Host Flora Lichtman talks with Jain about how his fringe idea led to lifesaving cancer treatments. Guest: Dr. Rakesh K. Jain studies the biology of tumors at Harvard Medical School and Massachusetts General Hospital as a professor of radiation oncology.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

More than 400,000 children and adolescents will be diagnosed with cancer worldwide this year. Many treatments that are meant to save a child can leave them with lifelong side-effects, including heart damage, infertility and cognitive issues. But for the first time, precision medicine is using the tiniest tools – nanoparticles – to design tailor-made treatments to beat childhood cancer. Tune in to learn how precision medicine is changing the odds in the fight against childhood cancer with Professor Maria Kavallaris AM, a researcher whose own cancer diagnosis occurred at the same time as a career-changing opportunity to join the Children's Cancer Institute.See omnystudio.com/listener for privacy information.

With the right protocols (and the right team!), urology clinics can proactively manage the side effects of intravesical therapy. This in-studio episode from the 2025 NMIBC Creator Weekend™ series features unique perspectives from Vanderbilt nurse practitioner Meredith Donahue and surgical neuro-oncology nurse Brynn Moore, a surgical neuro-oncology nurse, both with focuses in urologic oncology. Hosted by Dr. Ruchika Talwar, we cover the practical and logistical considerations in intravesical therapy administration. --- This podcast is supported by: Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/ --- SYNPOSIS Donahue and Moore share their experiences with intravesical therapy, discussing practical issues such as patient management, scheduling, and handling side effects. They emphasize the importance of creating a supportive environment in clinics, proactive treatment plans, and ensuring effective communication among the multidisciplinary team. They also share resources and tips for nurses and nurse practitioners new to urologic oncology. --- TIMESTAMPS 00:00 - Introduction07:09 - Multidisciplinary Team Dynamics11:34 - Resources for Patients18:55 - Transvaginal Estrogen Cream26:56 - Optimizing Intravesical Therapy Clinics35:57 - The Importance of Multidisciplinary Collaboration36:27 - Conclusion

Interview with John Brognard, PhD

Interview with medical student Michael Sun

Board-certified urologist Dr. Jason B. Carter explains his role in the diagnosis of testicular cancer."It's important to understand that when you have a diagnosis like testicular cancer, to some degree, the urologist may be the quarterback in the beginning. With testicular cancer, the urologist is going to be the one you meet, get the initial procedures done, and do the post-op follow-up."I'm very fortunate to have an excellent radiation oncologist that I work with, and very fortunate to have a couple of very, very good medical oncologists that I work with."Definitely anytime you have any kind of cancer, including testicular cancer, it is always a team approach." He shares his insights on treating testicular patients at Unity Urology, his practice in East Tennessee. He has been providing quality urologic care since 2003 and opened Unity Urology in 2006 in Greenville, Tennessee. Other urologic conditions to know about: Dr. Carter talks about other urologic conditions such as low testosterone, other hormone therapies for men and women, infertility, incontinence, and erectile disfunction. He is a medical advisor for Aeroflow Urology.Dr. Carter's medical degree is from East Tennessee University. He completed a residency at the University Hospital and clinics in Columbia, Missouri. He is board-certified in urology by the American Board of Urology and a member of the American Urological Association and the Tennessee Medical Association. Send us a textSupport the showFind us on Twitter, Instagram, Facebook & Linkedin. If you can please support our nonprofit through Patreon.

Join the October Menopause Challenge: https://drgabriellelyon.com/forever-strong-menopause-challenge/Pre-Order The Forever Strong PLAYBOOK and receive exclusive bonuses: https://drgabriellelyon.com/playbook/Want ad-free episodes, exclusives and access to community Q&As? Subscribe to Forever Strong Insider: https://foreverstrong.supercast.comWhen you hear the word “radiation,” do you think of cancer, Chernobyl, or an airport scanner? In this powerful episode, Dr. Gabrielle Lyon sits down with Dr. Sanjay Mehta, a radiation oncologist, to completely redefine your understanding of radiation as a tool for medicine.Dr. Mehta reveals how modern technology has made radiation oncology incredibly precise, minimizing side effects for cancer patients. He also shares groundbreaking insights into the underutilized field of low-dose radiation therapy, a safe and effective treatment for common inflammatory conditions like arthritis, tendinitis, and plantar fasciitis. This conversation is a must-watch for anyone with chronic pain or a fear of radiation, offering a new path to health and healing.Chapter Markers0:00 - Intro0:42 - The biggest myths about radiation1:33 - Dr. Sanjay Mheta's introduction2:07 - Radiation as a treatment for prostate cancer3:41 - The side effects of surgery vs. radiation4:32 - The training of a radiation oncologist5:34 - Full-body scans and diagnosis7:48 - What is radiation?9:00 - The difference between medicine and poison10:50 - The electromagnetic spectrum12:21 - Ionizing vs. Non-ionizing radiation13:42 - How we are naturally exposed to radiation15:50 - The biggest myth about radiation18:50 - Hormesis and low-dose radiation21:10 - The evolution of radiation technology22:38 - Radiation in daily life (dentist X-rays)25:00 - Can all cancers be destroyed by radiation?26:43 - Why radiation doesn't always burn skin28:25 - How radiation treatment is planned32:27 - Side effects of prostate cancer surgery33:09 - Penile shortening and prostate surgery36:00 - The role of testosterone in prostate cancer38:37 - How radiation affects bodybuilders39:09 - Who is not a candidate for radiation?41:33 - Is radiation the standard of care for all cancers?42:32 - Debunking radiation fear (microwaves, etc.)44:38 - The airport scanner debate47:03 - Other sources of radiation exposure52:32 - Grounding and radiation54:40 - Low-dose radiation for musculoskeletal injuries55:50 - The history of low-dose radiation57:22 - The use of radiation in the 1800s59:42 - Cortisone vs. low-dose radiation for pain1:03:00 - Dr. Ma's personal story of treatment1:04:07 - The duration and protocol of low-dose radiation1:08:16 - Inflammation and low-dose radiation1:10:59 - The durability of radiation therapy1:12:00 - Reversal of disease1:17:22 - Radiation's effect on hip pain1:18:29 - Treating rheumatoid arthritis1:20:29 - Post-operative radiation1:22:11 - Low-dose radiation for Peyronie's disease1:24:42 - What's holding back adoption of this therapy in the US?1:26:45 - The future of low-dose radiation1:27:31 - How to book an appointment with Dr. Mehta1:28:09 - Closing RemarksWho is Dr. Sanjay Mehta? Dr. Sanjay Mehta has been treating cancer patients for over 25 years using state of the art radiation oncology technology. He is now successfully treating patients with arthritis, tendonitis, and plantar fasciitis with low dose radiation using proven European regimens. It is non invasive, painless, and covered by Medicare and most insurance plans.This episode is brought to you by:PaleoValley - Get 15% off automatically at

Joining Pat this morning was Professor John Crown Consultant medical oncologist St Vincent's Hospital Group Professor of Translational Cancer Research DCU. John discusses the 18th International Symposium On Translational Research in Oncology taking place next week and the developments on cancer treatments.

Aotearoa is at least a decade behind in blood cancer treatments, and that is driving highly trained doctors offshore, as well as patients according, a New Zealand haematologist working in Australia. It comes as blood cancer patients with Meyloma are forced to move to Australia to get drugs that cost hundreds of thousands of dollars here but are virtually free across the Tasman. New Zealand-trained haematologist Professor Judith Trotman works in Sydney and treats medical migrants from Aotearoa, she spoke to Lisa Owen.

Trump admin cuts demolish cancer treatments for kids // Epstein's birthday book wasn't a hoax // AGREE TO DISAGREE: Bribing your kids? // WE HEAR YOU! and WORDS TO LIVE BY

Ready to delve into the critical intersection of cardiology and oncology? In this episode, Dr. Fernando Mendoza and Dr. Peyman Kabolizadeh unravel the intricacies of heart health during cancer treatment. Discover the potential heart complications that may arise from radiation therapy and the innovative technologies at MemorialCare Todd Cancer Institute designed to mitigate these risks. Whether you're a patient, caregiver, or health care enthusiast, this insightful discussion promises to equip you with the knowledge to navigate the complex landscape of cancer treatment while safeguarding heart health.

In a conversation with CancerNetwork®, Geraldine O'Sullivan Coyne, MD, MRCPI, PhD, spoke about her new appointment as the principal investigator and director of Clinical Research at the Northwell Health unit of the Southern Texas Accelerated Research Therapeutics (START) Center for Cancer Research. Based on a strategic partnership formed between Northwell Health and START in May 2024, she will oversee early-phase clinical trial development at New York's first START research site at the R.J. Zuckerberg Cancer Center in New Hyde Park. Coyne began by sharing her excitement to put all her efforts into making the unit a “good opportunity” to consider patients who reside in community settings for enrollment in new clinical trials. Although large academic centers may offer possibilities for enrolling in trials, Coyne highlighted how many patients may need to travel or leave their social networks behind as they undergo treatment, thus illustrating a need for expanded options in the community setting. “Having the privilege to be able to bring trial opportunities into the community—into the heart of the community—is what we are aiming to do,” Coyne stated about her new role. “We do believe that this will [allow] patients to access novel and powerful therapies that are now increasingly part of a personalized treatment paradigm for patients with advanced malignancies.” Emphasizing the pursuit of early-phase clinical investigations, Coyne described how the new unit may leverage START's expertise to advance novel molecules across all stages of the drug development pipeline up to regulatory approval. She noted that being able to safely create and refine new therapeutic approaches in the community setting lies at the heart of a successful collaboration between Northwell Health and START. “A lot of the excitement surrounding the START unit and Northwell Health collaboration with them is exploring these novel molecules that will hopefully continue to build on the pursuit in oncology drug development, which has been finding better and more targeted therapies for patients in their treatment journey,” Coyne said. Reference Olt B. Northwell names Geraldine O'Sullivan Coyne, MD, PhD, to lead clinical trials at new START center. News release. Northwell Health. July 22, 2025. Accessed August 12, 2025. https://tinyurl.com/bdcua8ck

TerraPower says there's potential in harnessing nuclear waste to fuel new cancer treatments. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Cancer Therapies You're Not Being Told About This episode goes straight into the treatments that rarely make it past the walls of a conventional oncology clinic. I'm talking red light therapy, chlorine dioxide solution (CDS), and even urine therapy, modalities backed by real science, used around the world, and showing results in cancer recovery, thyroid health, autoimmune conditions, wound healing, autism, chronic fatigue, and more. I'm joined by Jonathan Otto, researcher, educator, and producer of groundbreaking health documentaries who pulls back the curtain on what's working for patients right now. He shares case studies you won't hear in a standard medical appointment, breaks down the research hiding in plain sight, and explains exactly how these approaches fit into real-world healing protocols. We're also taking on the myths, the misinformation, and the reasons therapies with Nobel Prize-level science behind them are still being ignored. This is a candid, fact-driven conversation designed to help you see your options clearly, so you can make informed decisions about your health without limits placed on you by outdated systems. If you've been told there's only one path forward, this episode will give you a much wider view. Connect with Jonathan Otto: Instagram: @jonno.otto

Send us a textWelcome to The Oncology Journal Club Podcast Series 3Hosted by Professor Craig Underhill, Dr Kate Clarke & Professor Christopher Jackson | Proudly produced by The Oncology NetworkWelcome to Episode 6 of The Oncology Journal Club podcast. This is where we take a famously different approach to oncology research.Has non-operative management finally found its place in treating certain cancers? This episode unpacks compelling new data that might challenge the surgeon's traditional role for some patients with mismatch repair deficient tumours. While rectal cancer patients show remarkable complete response rates to immunotherapy, the story gets more complex across different cancer types – raising fascinating questions about tumour biology, patient selection and the future of organ preservation.We explore the delicate art of discussing immunotherapy outcomes with patients, navigating that narrow path between hope and realism. When treatments occasionally produce dramatic responses but more commonly offer limited benefits, how do oncologists communicate effectively without creating unrealistic expectations? Our hosts share practical strategies for these challenging conversations, emphasising that truly patient-centred care requires ongoing dialogue about prognosis.The oncology research world is evolving too, with updated CONSORT and SPIRIT guidelines transforming how clinical trials are designed and reported. These frameworks now mandate greater transparency, clearer safety reporting and increased patient involvement in study design – potentially leading to more trustworthy and applicable research outcomes.Plus, we examine an intriguing Chinese trial showing remarkable survival benefits from low-dose continuous capecitabine combined with aromatase inhibitors for metastatic breast cancer – a potential game-changer for resource-limited settings.From this year's AACR meeting, we highlight what might be the first change in standard of care for locally advanced head and neck cancer in two decades, along with promising targeted therapies for specific molecular subtypes of lung cancer. Join our expert hosts Professor Craig Underhill, Dr. Kate Clarke and Professor Christopher Jackson as they navigate these developments with their trademark blend of critical analysis, clinical wisdom and humour. Subscribe to The Oncology Newsletter to stay informed about the evolving landscape of oncology care and research.For links to the abstracts and bios of our hosts, head to the show notes on oncologynetwork.com.au.The Oncology Podcast - An Australian Oncology Perspective

Human Papillomavirus (HPV) is a small DNA virus that infects skin and wet surfaces of the body. The virus is typically spread through vaginal, anal, or oral sex. There are over 100 different types of HPV. The most common types of HPV are found on the skin and appear as warts. It is one of the most common types of sexually transmitted infections worldwide. HPV is responsible for more than 90% of anal and cervical cancers. The high-risk types of HPV form in the back of the throat, also known as Oropharyngeal Cancer. Vivian F. Wu, MD, MPH, is a surgeon-scientist specializing in all cancers of the head and neck, including those of the tongue, throat, voice box, thyroid, skin, and salivary glands. She is the Director of the Head and Neck Cancer Center of Excellence at Saint John's Cancer Institute and Pacific Neuroscience Institute (PNI).

JCO Editorial Fellow Dr. Lauren Shih and JCO Associate Editor Dr. Stephanie Wheeler discuss the ASCO 25 Simultaneous Publication paper "Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Lauren Shih: Hello, and welcome to our 2025 ASCO annual meeting series where we cover some of the top JCO papers published simultaneously with their abstract presentations at this year's meeting. I'm your host, Dr. Lauren Shih, JCO editorial fellow, and I'm joined by JCO Associate Editor Dr. Stephanie Wheeler to discuss the Journal of Clinical Oncology article and abstract presentation "Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare." Let's start with the relevance of the article. Dr. Wheeler, can you explain this to our listeners? Dr. Stephanie Wheeler: Thank you so much. Let's get right into it. So this article is really about understanding different types of Medicare plans and what we should expect to see in terms of their use of low-value treatments for cancer patients. So, as Medicare really is focused on trying to limit the use of low-value cancer treatments, we really need to better understand the drivers of variability. So we know that many cancer patients have multiple treatment options available to them. We also know that the vast majority of older adults beyond age 65 are insured by Medicare, and about half of them are on Medicare Advantage plans, which are serviced by private insurance. And private insurance companies in this case are receiving capitated payments for Medicare beneficiaries to manage their service utilization and reduce costs. So, with respect to Medicare Advantage versus the traditional fee-for-service Medicare, it's not really been known to what extent low-value treatments are differentially used by these types of plans for cancer patients. And so that was really the focus of this article. What the authors found is that across six different types of treatments, in general, the folks who were enrolled in Medicare Advantage plans had reduced use of low-value treatment. So that's a good sign for Medicare beneficiaries. And although the relative difference in that use was somewhat low, this translates to a significant number of Medicare enrollees across the country not receiving these low-value treatments. And of course, this translates to considerable savings at the society level. Dr. Lauren Shih: Are there any additional key results that we should review? Dr. Stephanie Wheeler: Yeah. So I'll tell you just a little bit more about the methods and also their findings. So they looked at six different low-value treatments, and this was in, again, 100% of national Medicare enrollees from 2015 through 2021. So the six low-value treatments that they examined were the use of G-CSFs among patients receiving low-risk chemotherapy and denosumab for those who had castration-sensitive prostate cancer. Then they also looked at four high-cost treatments, including using nab-paclitaxel instead of paclitaxel for patients with breast or lung cancer; second, adding bevacizumab to carboplatin plus paclitaxel for ovarian cancer; third, using brand-name drugs instead of generics when generics were available; and fourth, using biologics instead of biosimilars when biosimilars were available. And these are all, by the way, non-recommended treatments according to a variety of guidelines, including NCCN and ASCO's Choosing Wisely guidelines. So they used the Medicare claims data to examine use of these regimens. They also analyzed results by type of Medicare Advantage plan, whether people were enrolled in a health maintenance organization plan, or an HMO, or a preferred provider organization plan, or a PPO. They also looked at the largest Medicare Advantage insurers—including Aetna, Blue Cross Blue Shield, Cigna, Humana, and UnitedHealth—and limited their analyses to those that had complete encounter data. And what they found across the board is that the enrollees in Medicare Advantage plans generally had lower use of these low-value treatments. And the largest differences between Medicare Advantage and traditional Medicare plans were in the outcomes, including G-CSF use and using denosumab for castration-resistant prostate cancer, and then the combination of bevacizumab, carboplatin, and paclitaxel versus carboplatin and paclitaxel. And all of these had a change in use ranging from about 19% change to 24% change in use. This is significant as a field as we look at ways in which different plan organization can influence use of treatments, particularly given the excess cost of cancer care. This is something we really want to pay attention to. So I'd encourage folks to look more closely at the results by treatment type as well as the results by plan type to see a little bit more about what was going on across different plan types. Dr. Lauren Shih: Great. And are there any outstanding questions that need to be answered? Dr. Stephanie Wheeler: Yes, there always are, of course. I think the study has several strengths that are worth noting. First, they have 100% of Medicare enrollees, so there's national coverage there, which is, you know, quite outstanding. They also use an appropriate choice of analysis to help deal with some of the selection. So they use inverse probability of treatment weights, and they control for practice and county indicators to try to get some realistic adjustment for the selection that happens in terms of how patients are enrolled in different Medicare Advantage versus traditional fee-for-Medicare plans. These statistical approaches are a good idea, but they are limited by the observed variables that we can use for these kinds of adjustments. And so any unobserved—confounding or any unobserved factors that would influence selection in these plans aren't going to be captured well. So preferences, for example, that patients may have about different types of plans when they're insuring themselves and their families may not be captured. Second, the data that are used are only encounter data from those plans with complete records. That may mean that smaller Medicare Advantage insurers or those that don't have as comprehensive records are not included. So this may not be reflective of their practice patterns. And then third, of course, this only looked at six different low-value cancer treatments. It remains to be seen whether this kind of finding extends to other types of low-value cancer treatments, and that's an opportunity for future study. Finally, I would say that we don't exactly know why these patterns exist. It could be that Medicare Advantage plans have different approaches to prior authorization. They could have more in-house quality control and management to really understand, among their population for whom they're receiving Medicare Advantage payments, to really look at care quality and assess Choosing Wisely guidelines. We don't know exactly how that's playing out. And so we need additional data to really figure out what's working here and what are opportunities for future policy and payment innovations that can further reduce low-value care. Dr. Lauren Shih: Great. Thank you so much, Dr. Wheeler, for speaking to us about the JCO article, "Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare." We really appreciate your insights. Dr. Stephanie Wheeler: Thanks for having me. Dr. Lauren Shih: Join us again for the latest simultaneous publications from the ASCO 2025 Annual Meeting. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

This is the daily Tech and Business Report. Today, KCBS Radio anchor Eric Thomas spoke with Bloomberg's Robert Langreth. The cost of cancer drugs has been skyrocketing, but now questions are being raised about just how beneficial they are. A recent analysis in JAMA Oncology found that a drop in cancer deaths between 1975 and 2020 was due mostly to improved screening and preventative health measure, and not new treatments.

Dr. Jennifer Wargo is an Associate Professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center and a Stand Up To Cancer researcher. Jennifer is a physician scientist, and this means she splits her time between providing care to patients and doing research to find better ways of treating disease. Specifically, Jennifer performs surgeries and treats patients one day each week. She spends the rest of her week studying how to better treat patients with cancer and how cancer may ultimately be prevented. When she's not doing research or treating patients, Jennifer enjoys spending quality time with her family. Some of their favorite activities include going for walks, biking, hiking, and visiting the beach. Jennifer also likes to explore her creative side through art and photography, as well as to be active through running, biking, yoga, and surfing. She received her A.S. degree in nursing and B.S. degree in biology from Gwynedd-Mercy College. Afterwards, Jennifer attended the Medical College of Pennsylvania where she earned her M.D. Jennifer completed her Clinical Internship and Residency in General Surgery at Massachusetts General Hospital. Next, Jennifer was a Research Fellow in Surgical Oncology at the University of California, Los Angeles. She then accepted a Clinical Residency in General Surgery at Massachusetts General Hospital. From 2006-2008, Jennifer was a Clinical Fellow in Surgical Oncology at the National Cancer Institute of the National Institutes of Health. She then served on the faculty at Massachusetts General Hospital and Harvard University. In 2012, Jennifer received her MMSc. degree in Medical Science from Harvard University. Jennifer joined the faculty at The University of Texas MD Anderson Cancer Center in 2013. She is Board Certified by the American Board of Surgery, and she has received numerous awards and honors throughout her career. These have included the R. Lee Clark Prize and Best Boss Award from the MD Anderson Cancer Center, the Rising STARS and The Regents' Health Research Scholars Awards from the University of Texas System, the Outstanding Young Investigator and Outstanding Investigator Awards from the Society for Melanoma Research, as well as a Stand Up To Cancer Innovative Research Grant for her microbiome work. She has also received other awards for excellence in teaching, research, and patient care. In our interview, Jennifer shares more about her life and science.

CAR T-cell therapy is giving hope to cancer patients around the world. While not currently available in New Zealand, a clinical trial is underway at Wellington's Malaghan Institute.

In this episode of Better Than Before Breast Cancer™, we're talking about a common and little-talked-about side effect of breast cancer treatment and day-to-day living: digestive changes. If you've experienced bloating, reflux, fatigue, or that uncomfortable feeling of fullness after eating, this episode is for you. You'll learn why hypochlorhydria (low stomach acid) is often misdiagnosed as high stomach acid, how breast cancer treatments like chemotherapy, radiation, and hormonal therapy contribute to poor digestion, and why treating symptoms with acid-blocking medications might be doing more harm than good. Most importantly, we'll cover simple, nurturing steps — like mindful eating habits and nutrient support — to help you feel better, absorb more nutrients, and reconnect with your body's healing capacity.  

- Health Freedom Movement and Nomination of Casey Means (0:00) - Hijacking of the Health Freedom Movement (2:29) - Trust in Government and Establishment Control (6:01) - Investigative Journalism and Epstein Files (6:40) - Delayed Promises and False Hope (11:43) - Introduction to Scott Gordon and Prompting AI Engines (17:24) - AI Reasoning and Natural Intelligence (21:21) - Practical Tips for Using AI Engines (47:36) - Ethical Considerations and Future Plans (1:13:12) - Enoch AI and Its Limitations (1:14:50) - Enoch AI's Capabilities and Future Improvements (1:28:28) - Introduction to "The Cancer Industry" Book (1:31:02) - Critique of Cancer Treatments and Industry Practices (1:37:45) - Mother's Day Special and Health Ranger Store Promotions (1:38:06) - Announcement of "Breaking the Chains" Docu Series (1:42:03) - Detailed Overview of "Breaking the Chains" Content (1:53:04) - Introduction to Unincorporated Nonprofit Associations (UNAs) (1:55:46) - Final Thoughts and Call to Action (2:03:18) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Nightlife explores a growing tourism trend with Tracy King, who has recently undergone two procedures overseas, and Dr Mark Frydenberg from the Royal Australasian College of Surgeons, joining Philip Clark to discuss the rewards and risks. 

- Overview of Common Eye & Vision Changes Related to Cancer Treatments - Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors - Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights - The Role of the Multidisciplinary Team - Tips to Manage Low Vision & How Eye Products Can Help You Manage Eye/Vision Changes - Clinical Trials: How Research Increases Your Treatment Options - Communicating with Your Health Care Team - Guidelines for Eye Examinations & Check-Ups - Quality-of-Life Concerns - Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of Open Notes - Questions for Our Panel of Expert

- Overview of Common Eye & Vision Changes Related to Cancer Treatments - Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors - Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights - The Role of the Multidisciplinary Team - Tips to Manage Low Vision & How Eye Products Can Help You Manage Eye/Vision Changes - Clinical Trials: How Research Increases Your Treatment Options - Communicating with Your Health Care Team - Guidelines for Eye Examinations & Check-Ups - Quality-of-Life Concerns - Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of Open Notes - Questions for Our Panel of Expert

- Overview of Common Eye & Vision Changes Related to Cancer Treatments - Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors - Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights - The Role of the Multidisciplinary Team - Tips to Manage Low Vision & How Eye Products Can Help You Manage Eye/Vision Changes - Clinical Trials: How Research Increases Your Treatment Options - Communicating with Your Health Care Team - Guidelines for Eye Examinations & Check-Ups - Quality-of-Life Concerns - Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of Open Notes - Questions for Our Panel of Expert

- Overview of Common Eye & Vision Changes Related to Cancer Treatments - Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors - Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights - The Role of the Multidisciplinary Team - Tips to Manage Low Vision & How Eye Products Can Help You Manage Eye/Vision Changes - Clinical Trials: How Research Increases Your Treatment Options - Communicating with Your Health Care Team - Guidelines for Eye Examinations & Check-Ups - Quality-of-Life Concerns - Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of Open Notes - Questions for Our Panel of Expert

- Overview of Common Eye & Vision Changes Related to Cancer Treatments - Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors - Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights - The Role of the Multidisciplinary Team - Tips to Manage Low Vision & How Eye Products Can Help You Manage Eye/Vision Changes - Clinical Trials: How Research Increases Your Treatment Options - Communicating with Your Health Care Team - Guidelines for Eye Examinations & Check-Ups - Quality-of-Life Concerns - Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of Open Notes - Questions for Our Panel of Expert

- Overview of Common Eye & Vision Changes Related to Cancer Treatments - Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors - Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights - The Role of the Multidisciplinary Team - Tips to Manage Low Vision & How Eye Products Can Help You Manage Eye/Vision Changes - Clinical Trials: How Research Increases Your Treatment Options - Communicating with Your Health Care Team - Guidelines for Eye Examinations & Check-Ups - Quality-of-Life Concerns - Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of Open Notes - Questions for Our Panel of Expert

- Overview of Common Eye & Vision Changes Related to Cancer Treatments - Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors - Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights - The Role of the Multidisciplinary Team - Tips to Manage Low Vision & How Eye Products Can Help You Manage Eye/Vision Changes - Clinical Trials: How Research Increases Your Treatment Options - Communicating with Your Health Care Team - Guidelines for Eye Examinations & Check-Ups - Quality-of-Life Concerns - Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of Open Notes - Questions for Our Panel of Expert

- Overview of Common Eye & Vision Changes Related to Cancer Treatments - Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors - Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights - The Role of the Multidisciplinary Team - Tips to Manage Low Vision & How Eye Products Can Help You Manage Eye/Vision Changes - Clinical Trials: How Research Increases Your Treatment Options - Communicating with Your Health Care Team - Guidelines for Eye Examinations & Check-Ups - Quality-of-Life Concerns - Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of Open Notes - Questions for Our Panel of Expert

PREVIEW: Colleague Gregory Copley speaks of the good news of King Charles' return to work after a rest for the cancer treatments. More later. 1817 CHARLES I.

Got Health Questions or Comments?

BUFFALO, NY - March 25, 2025 – A new #review was #published in Oncotarget, Volume 16, on March 13, 2025, titled “Signaling pathway dysregulation in breast cancer." In this review article, Dinara Ryspayeva and colleagues from Brown University provide a detailed look at how breast cancer cells change the way they communicate and grow—helping tumors survive, spread, and resist treatment. The review highlights how certain gene mutations and disrupted signaling pathways influence therapy response across different types of breast cancer. It also outlines current treatment strategies and clinical trials, offering insights that could improve care for patients with aggressive or hard-to-treat cancers. Breast cancer is the most common cancer in women and a major cause of cancer-related deaths worldwide. While many patients respond to treatment at first, some cancers return or stop responding. The review explores how signaling disruptions inside tumor cells are often behind these setbacks. The authors discuss several major pathways involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch, NF-κB, and the DNA damage response (DDR). These pathways help control cell growth, division, DNA repair, and survival. When altered by mutations or other changes, they can promote tumor progression and resistance to treatment. One of the most disrupted pathways is PI3K/Akt/mTOR. It plays a central role in cell growth, but in many breast cancers—especially hormone receptor-positive and HER2-positive types—it becomes overactive due to gene mutations, or the loss of a tumor-suppressing protein called PTEN. “Up to 25–40% of BC cases exhibit variations that hyperactivate the PI3K/Akt/mTOR pathway, underscoring its critical role in oncogenesis.” Another key pathway, RAS/RAF/MEK/ERK, can also promote tumor growth. Even without mutations, it may become active when primary pathways are blocked, particularly in HER2-positive and triple-negative breast cancers. The review also highlights several new and emerging treatments aimed at blocking down these signaling pathways. Some drugs are already approved, while others are in clinical trials. The authors suggest that combining different treatments may help stop multiple pathways at once, making it harder for cancer cells to adapt. Matching treatments to each tumor's unique genetic changes could also improve patient outcomes. This comprehensive review gives researchers and clinicians a clearer understanding of how breast cancer resists treatment and where future therapies should focus. A better understanding of these disrupted signaling systems could lead to more personalized and effective treatments for patients facing aggressive or recurring disease. DOI - https://doi.org/10.18632/oncotarget.28701 Correspondence to - Dinara Ryspayeva - dinara_ryspayeva@brown.edu Video short - https://www.youtube.com/watch?v=ppFVGwdztHI Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Lisa Vanderpump announces major new moves in Las Vegas, is she one step closer to having a reality show there. Plus, who is the leak behind Kyle and Mauricio's divorce rumors, cheating rumors, and Morgan Wade hookup rumors? David Yontef from ‘Behind The Velvet Rope' podcast joins and dishes on Teddi Mellencamp and the latest news with her cancer battle. Plus, Paige and Craig update and can you believe that as we record this Karen Huger is in jail, WILDDDDD! Get Tickets To Our Virtual Live Podcast show May 1st at 7pm EDT. Here's the link for tickets: https://www.eventbrite.com/e/david-yontef-sarah-fraser-virtual-live-show-ask-us-anything-51-7pm-tickets-1276780297239?aff=erelexpmlt MY Go Big Podcasting Courses Are Here! Purchase Go Big Podcasting and learn to start, monetize, and grow your own podcast. USE CODE: Cyber10 for 10% OFF**SHOP my Amazon Marketplace - especially if you're looking to get geared-up to start your own Podcast!!!**https://www.amazon.com/shop/thesarahfrasershowShow is sponsored by:Amazfit.com/tsfs are the best, most affordable, and long-lasting performance watches! Use code TSFS for 10% OFFHometownHero.com for the BEST CBD and THC products that support Veterans, and use code TSFS to take 20% off your first purchaseHorizonfibroids.com get rid of those nasty fibroidsJunesJourney download the free game in the app store, find clues and solves mysteries with this fun game.LittleSaints.com use code TSFS for 20% off your first order, these are my FAV non-alcoholic cocktails, enjoy better sleep, less stress, and more!MeetFabric.com/TSFS join the thousands of parents who trust Fabric to help protect their family. Apply today in just minutesNutrafol.com use code TSFS for FREE shipping and $10 off your subscriptionProlonlife.com/tsfs 15% off sitewide plus a $40 bonus gift when you subscribe to their 5-Day Nutrition Program! ● Try their detox that has REAL FOOD and WORKS!Rula.com/tsfs to get started today. That's R-U-L-A dot com slash tsfs for convenient therapy that's covered by insurance.Quince.com/tsfs for FREE shipping on your order and 365 day returnsFollow me on Instagram/Tiktok: @thesarahfrasershow  ***Visit our Sub-Reddit: reddit.com/r/thesarahfrasershow for ALL things The Sarah Fraser Show!!!***Advertise on The Sarah Fraser Show: thesarahfrasershow@gmail.comGot a juicy gossip TIP from your favorite TLC or Bravo show? Email: thesarahfrasershow@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Lisa Vanderpump announces major new moves in Las Vegas, is she one step closer to having a reality show there. Plus, who is the leak behind Kyle and Mauricio's divorce rumors, cheating rumors, and Morgan Wade hookup rumors? David Yontef from ‘Behind The Velvet Rope' podcast joins and dishes on Teddi Mellencamp and the latest news with her cancer battle. Plus, Paige and Craig update and can you believe that as we record this Karen Huger is in jail, WILDDDDD!  Get Tickets To Our Virtual Live Podcast show May 1st at 7pm EDT. Here's the link for tickets: https://www.eventbrite.com/e/david-yontef-sarah-fraser-virtual-live-show-ask-us-anything-51-7pm-tickets-1276780297239?aff=erelexpmlt  MY Go Big Podcasting Courses Are Here! Purchase Go Big Podcasting and learn to start, monetize, and grow your own podcast. USE CODE: Cyber10 for 10% OFF **SHOP my Amazon Marketplace - especially if you're looking to get geared-up to start your own Podcast!!!** https://www.amazon.com/shop/thesarahfrasershow Show is sponsored by: Amazfit.com/tsfs are the best, most affordable, and long-lasting performance watches! Use code TSFS for 10% OFF HometownHero.com for the BEST CBD and THC products that support Veterans, and use code TSFS to take 20% off your first purchase Horizonfibroids.com get rid of those nasty fibroids JunesJourney download the free game in the app store, find clues and solves mysteries with this fun game. LittleSaints.com use code TSFS for 20% off your first order, these are my FAV non-alcoholic cocktails, enjoy better sleep, less stress, and more! MeetFabric.com/TSFS join the thousands of parents who trust Fabric to help protect their family. Apply today in just minutes Nutrafol.com use code TSFS for FREE shipping and $10 off your subscription Prolonlife.com/tsfs 15% off sitewide plus a $40 bonus gift when you subscribe to their 5-Day Nutrition Program! ● Try their detox that has REAL FOOD and WORKS! Rula.com/tsfs to get started today. That's R-U-L-A dot com slash tsfs for convenient therapy that's covered by insurance. Quince.com/tsfs for FREE shipping on your order and 365 day returns Follow me on Instagram/Tiktok: @thesarahfrasershow   ***Visit our Sub-Reddit: reddit.com/r/thesarahfrasershow for ALL things The Sarah Fraser Show!!!*** Advertise on The Sarah Fraser Show: thesarahfrasershow@gmail.com Got a juicy gossip TIP from your favorite TLC or Bravo show? Email: thesarahfrasershow@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

On today's episode of The Medical Alley Podcast, we welcome Francis Medical's President and CEO Mike Kujak.Named after the founder of the company's father who went through his own cancer journey, Francis Medical is on a mission to develop urological cancer treatments that are, "tough on cancer yet gentle on patients." In this conversation, Mike talks about that mission, his own background in the medical device ecosystem, and some deep, personal connections to Francis Medical's work.Send us a message! Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram.

In this episode, Heather opens up about her journey through diagnosis and treatment, sharing the raw and real moments that defined her experience. She reflects on the toughest times and how she found the strength to push through. Tune in for an honest and powerful conversation about resilience, self-discovery, and navigating life's hardest challenges. Join the 5 to Thrive Challenge: https://heatherjose.com/ Download the 5 to Thrive: https://heatherjose.com/ols/products/... Little Pink Houses of Hope - https://www.littlepink.org/ Follow Heather's Socials: Instagram: HeatherJose LinkedIn:   / heather-jose-a4085219   Youtube: @ImStillHere1298 In this empowering episode, Heather shares profound insights gained from her remarkable 25-year journey as a metastatic breast cancer survivor. Join us as we delve into essential topics like cancer survivorship, where Heather imparts valuable mental health advice and coping strategies for cancer patients. From navigating hospitals to post-treatment tips, Heather's candid and compassionate narrative serves as a beacon of strength. Tune in for an intimate exploration of coping mechanisms, including Heather's personal journey insights, as she imparts wisdom on resilience, hope, and living life to the fullest despite the challenges of metastatic breast cancer. If you or a loved one is seeking authentic guidance, this episode provides a wealth of information, ensuring that no one faces this journey alone. #MetastaticBreastCancer #Deconstruct #Deconstruction #CancerSurvivor #ThrivingWithCancer #MentalHealthMatters #NutritionForWellness #MedicalAdvancements #MindfulnessJourney #ResiliencePodcast #PatientAdvocacy #TreatmentInsights #SurvivorStories #PodcastHope #CommunitySupport #EmpowermentPodcast #LivingBeyondDiagnosis #PositiveMindset #WellnessWednesday #CancerAwareness

On this episode, we will hear from naturopathic oncologist, Dr. Ellen Conte. Dr. Conte shares her experience doing research on natural cancer treatments and highlights some exciting clinical trials. She also talks about the unique challenges and opportunities in integrative cancer research.Five To Thrive Live is broadcast live Tuesdays at 7PM ET and Music on W4CS Radio – The Cancer Support Network (www.w4cy.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com). Five To Thrive Live Podcast is also available on Talk 4 Media (www.talk4media.com), Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.

Breast cancer rates are on the rise—especially for women under 40. So, what's going on? Today, we discuss breast cancer rates, detection, and controversies with Dr. Jenn Simmons, a board-certified breast surgeon and integrative oncologist. In this episode, she shares when mammograms are necessary, and when they're not. We also cover root causes, holistic treatments, and pitfalls with the current standard of care. Timestamps:[1:50] Welcome to the Well Fed Women podcast[3:39] Why are we seeing an explosion of breast cancer in younger women?[7:42] Is there a difference between bioidentical hormones and birth control and is there a connection between hormone replacement therapy and breast cancer?[15:38] What, in your opinion, are some of the top things that women are exposed to on a regular basis that are contributing to breast cancer?[31:41] Is there any research that suggests mammograms reduce rates of dying from breast cancer or catching it early?[39:33] Are biopsies sage or could they do more harm?[40:30] Can you treat breast cancer without radiation?[49:17] What is the deal with thermography?[1:02:31] What are some of the common pitfalls of the standard treatment women receive after diagnosis?Episode Links:Real Health MD websiteQT ImagingJoin Dr. Jenn's GroupFollow Dr. Jenn on InstagramSubscribe to Dr. Jenn on YouTubeKeeping Abreast with Dr. Jenn PodcastThe Smart Woman's Guide to Breast Cancer Auria® Home Breast Health Assessment Use coupon code DRJENN20 for 20% off Sponsors:Go to https://thisisneeded.com/  and use coupon code WELLFED for 20% off your first order.Go to http://mdlogichealth.com/drschoice, and use coupon code WELLFED for 10% off.Go to boncharge.com/WELLFED and use coupon code WELLFED to save 15% off any order.Go to wellminerals.us/adrenal-stress-less/ and use code WELLFED to get 10% off your order.

In this episode of Moms of the Lou, Rebekah sits down with Kira Andersen, a St. Louis mom and health and wellness coach. Kira shares her family's journey with her husband Kyle's stage four pancreatic cancer diagnosis in October 2021. Despite initial misdiagnoses and a dire prognosis, Kira relentlessly advocated for advanced treatments. She raised funds to access a promising drug in order to help her husband. Kyle underwent treatment, including chemo and immunotherapy, but faced numerous challenges, including hospitalizations and blood transfusions. Kira's story highlights the importance of being a health advocate for your family and the complexities of accessing innovative cancer treatments. To learn more about Kira and her work, you can visit her website at https://www.kiraandersen.com/.Kira is a devoted mom to three young children, all under the age of 7. As a health and wellness coach and podcast host, she is passionate about inspiring growth—mentally, physically, and spiritually—in both her clients and herself. After losing her spouse to pancreatic cancer, Kira has embraced the role of a solo parent with strength and determination. She is deeply committed to raising awareness and critical funds for cancer research. Guided by a positive outlook, Kira strives each day to be the best mom, friend, and individual she can be.We hope you enjoyed this podcast episode! To learn more about Moms of the Lou you can go to stlouismom.com or follow us on Instagram and Facebook. You can listen to the podcast on Apple Podcast and Spotify. And don't forget to rate and review so more people can tune in! This episode was produced by the St. Louis Mom. It was recorded and edited by Half Coast Studios in St. Louis, Missouri. Music composed by Trina Harger.

#KING CHARLES REPORT:  Despite extended cancer treatments, Charles represents the strength of the Commonwealth.. Gregory Copley, Defense & Foreign Affairs. 1701 Charles II

00:48 Chemotherapy efficacy varies with the menstrual cycleBreast cancer cells are more susceptible to chemotherapy at certain points in the menstrual cycle, new data in Nature suggests. Researchers studied the equivalent hormonal cycle in mice and found that during the oestrous phase, where progesterone levels are low, tumours are more susceptible to chemotherapy. The same effect was shown in humans in a small retrospective study. The team caution that a larger clinical trial would need to be conducted, but hope that this work could open up an, easy to implement, way to boost the effect of chemotherapy.Research Article: Bornes et al.News and Views: What is the best time of the month to treat breast cancer?09:22 Research HighlightsHow coffee changes your gut microbiota, and the first amber deposits found in Antarctica hint at an ancient rainforest.Research Highlight: Do you drink coffee? Ask your gutResearch Highlight: Antarctica's first known amber whispers of a vanished rainforest11:47 Is human-level artificial intelligence close?The latest AI system released by OpenAI, the makers of ChatGPT, is better able to break down problems into smaller chunks, making it closer to a human way of solving problems than other systems. This has reignited discussions about the likelihood of AIs achieving human-level intelligence. Although previously the realm of science fiction, researchers are now taking the idea of ‘artificial general intelligence', or AGI, more seriously. Although this technology has the potential to help tackle humanity's biggest challenges, there are concerns about the safety of such technology if it were to become autonomous.News Feature: How close is AI to human-level intelligence?21:43 Briefing ChatHow making a bank of centenarians' stem cells could help unlock the secrets of healthy ageing, and what some 1.5 million year old footprints reveal about how ancient hominin species may have interacted.Nature: What's the secret to living to 100? Centenarian stem cells could offer cluesNature: These two ancient human relatives crossed paths 1.5 million years agoSubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Dr. Colleen Gaughan, thoracic surgeon at AdventHealth Celebration, joins the Becker's Healthcare Podcast during Lung Cancer Awareness Month to discuss advancements in early detection and her pioneering use of CYTALUX for intraoperative molecular imaging. Learn how these innovations are transforming lung cancer care and hear her advice for healthcare leaders.

BUY OUR MERCH HEREhttp://thegardenstate.comJoin the mail bag by leaving a voicemail at: 908-67-9999-3Welcome back to The Garden State, the only NJ podcast that gives you all the news you need to know this week. Thanks for tuning in once again and for supporting the podcast. If you're enjoying the show, make sure to leave us a review! We love reading those!Follow us on all our socials to keep up to date with that and everything else happening. https://linktr.ee/thegardenstate

#KING CHARLES REPORT: Back to work despite the cancer treatments. Gregory Copley, Defense & Foreign Affairs 1765 HMS Victory